NCT04257461View on ClinicalTrials.gov

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Small Bowel Adenocarcinoma
Interventions
DRUG

Fluoropyrimidine

Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.

DRUG

Oxaliplatin

Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.

Trial Locations (9)

1070

ULB Erasme, Brussels

1200

Cliniques Universitaires Saint-Luc UCL, Brussels

2300

AZ Turnhout, Turnhout

2650

UZ Antwerpen, Antwerp

4000

CHC MontLégia, Liège

CHU Liège, Liège

8800

AZ Delta, Roeselare

9000

AZ St-Lucas, Ghent

9300

Onze-Lieve-Vrouw Ziekenhuis Aalst, Aalst

Sponsors

Collaborators (1)

Cancer Research UK
All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Cancer Research UK

OTHER

lead

Belgian Group of Digestive Oncology

OTHER